Commission Decision (EU) 2022/459 of 10 September 2021 on the State aid SA.49668 ... (32022D0459)
Commission Decision (EU) 2022/459 of 10 September 2021 on the State aid SA.49668 ... (32022D0459)
COMMISSION DECISION (EU) 2022/459
of 10 September 2021
on the State aid SA.49668 (2019/C) (ex 2017/FC) and SA.53403 (2019/C) (ex 2017/FC) implemented by Denmark and Sweden for PostNord AB and Post Danmark A/S
(notified under document C(2021) 6568)
(Only the Danish and Swedish versions are authentic)
(Text with EEA relevance)
1.
PROCEDURE
2.
DETAILED DESCRIPTION OF THE AID
2.1.
Beneficiaries
2.1.1.
Post Danmark and PostNord AB
Figure 1
Corporate structure of PostNord
2.1.2.
The markets on which PostNord and Post Danmark operate
2.2.
Background of the measures under assessment
2.2.1.
Impact of digitisation on Post Danmark
Figure 2
Development in mail volumes in European postal service operators
|
MDKK |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
|
Revenue |
10 828 |
10 107 |
9 250 |
8 811 |
8 171 |
7 964 |
7 641 |
6 728 |
5 836 |
6 214 |
4 913 |
|
EBIT |
81 |
348 |
305 |
- 207 |
- 204 |
- 301 |
- 289 |
-1 178 |
- 790 |
-1 063 |
- 221 |
2.2.2.
October Agreement
2.2.3.
The Agreement on the implementation of the USO compensation
2.3.
Description of the measures under assessment
2.3.1.
The measures under assessment
2.3.2.
Capital injection from PostNord Group into Post Danmark
2.3.2.1.
Objective
2.3.2.2.
Amount and origin
2.3.2.3.
Timing
2.3.3.
Capital injection from Denmark into PostNord AB
2.3.3.1.
Objective
2.3.3.2.
Amount and origin
2.3.3.3.
Timing
2.3.4.
Capital injection from Sweden into PostNord AB
2.3.4.1.
Objective
2.3.4.2.
Amount and origin
2.3.4.3.
Timing
2.4.
ITD complaint
2.5.
The 2018 Decision
2.6.
Grounds for initiating the formal investigation procedure
2.6.1.
Capital injection from PostNord Group into Post Danmark
2.6.2.
Capital injection from Denmark into PostNord AB
2.6.3.
Capital injection from Sweden into PostNord AB
3.
COMMENTS FROM INTERESTED PARTIES
3.1.
ITD (the complainant)
3.1.1.
The three capital injections constitute one single measure
3.1.2.
The three capital injections were granted on the same date
3.1.3.
The capital injections constitute aid
3.1.3.1.
State resources, imputability, selectivity, distortion of competition and affection of trade
3.1.3.2.
Advantage of the capital injection from PostNord into Post Danmark
3.1.3.3.
Advantage of the capital injections from Denmark and Sweden into PostNord
3.2.
Dansk Distribution
3.3.
Dansk Scanning
3.4.
Danske Fragtmænd A/S
3.5.
Jørgen Jensen Distribution A/S
3.6.
UPS
3.6.1.
Capital injection from PostNord into Post Danmark
3.6.2.
Capital injections from Denmark and Sweden into PostNord
3.7.
Anonymous
4.
COMMENTS FROM DENMARK AND SWEDEN
4.1.
Joint comments from Denmark and Sweden on the opening decision
4.1.1.
The capital injections constitute three separate measures
4.1.2.
The three capital injections were granted on different dates
Figure 3
Timeline of the granting of the three capital injections:
4.1.3.
The capital injection from PostNord Group into Post Danmark does not involve State aid
4.1.3.1.
Joint comments by Denmark and Sweden on imputability, State resources and distortion of competition
4.1.3.2.
Joint comments by Denmark and Sweden on the non-existence of an advantage
|
(amounts in million DKK) |
||||||||||||
|
|
|
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
2026 |
Assumptions for Terminal Enterprise/Firm value |
|
EBITDA |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
Capex |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
Change in net working capital |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
USO equity capital injection |
|
|
1 161 |
|
|
|
|
|
|
|
|
|
|
Net increase of provisions |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
Tax on EBIT |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
FCFF (incl. USO) (Free Cash Flow to Firm) |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
WACC |
|
[…] % |
|
Terminal growth rate of FCFF |
|
[…] % |
|
Terminal Enterprise/Firm value |
|
[…] |
|
|
|
|
|
Present Value (PV) of FCFF |
(A) |
[…] |
|
PV of Terminal Enterprise/Firm value |
(B) |
[…] |
|
Enterprise/Firm value |
(C)=(A)+(B) |
[…] |
|
Net debt |
(D) |
[…] |
|
Equity value |
(E)=(C)-(D) |
[…] |
|
PV of Effects of bankruptcy |
(F) |
[…] |
|
PostNord Group’s equity losses in Post Danmark’s liquidation scenario |
(G)=(F)-(E) |
[…] |
|
PostNord Group’s capital injection |
(H) |
-2 339 |
|
(amounts in million DKK) |
|||||||||||||
|
|
|
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
|
2024 |
2025 |
2026 |
Assumptions for Terminal Equity value |
|
FCFF (incl. USO) (Free Cash Flow to Firm) |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
[…] |
[…] |
[…] |
[…] |
|
USO equity capital injection |
|
|
-1 161 |
|
|
|
|
|
|
|
|
|
|
|
Free Cash Flow to Firm (excl. USO) |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
[…] |
[…] |
[…] |
[…] |
|
Change in net debt |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
[…] |
[…] |
[…] |
|
|
Interest costs |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
[…] |
[…] |
[…] |
[…] |
|
Difference in tax between FCF to Firm and FCF to Equity |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
[…] |
[…] |
[…] |
[…] |
|
USO equity capital injection |
|
|
1 161 |
|
|
|
|
|
|
|
|
|
|
|
FCFE (incl. USO) (Free Cash Flow to Equity) |
|
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
[…] |
[…] |
[…] |
[…] |
|
Cost of equity |
|
[…] % |
|
Terminal growth rate of FCFE |
|
[…] % |
|
Terminal Equity value |
|
[…] |
|
|
|
|
|
PV of FCFE |
(A) |
[…] |
|
PV of Terminal Equity value |
(B) |
[…] |
|
Equity value |
(E)=(A)+(B) |
[…] |
|
PV of Effects of bankruptcy |
(F) |
[…] |
|
PostNord Group’s equity losses in Post Danmark’s liquidation scenario |
(G)=(F)-(E) |
[…] |
|
PostNord Group’s capital injection |
(H) |
-2 339 |
Balance sheet end of period
|
Date of cash flow |
31-Dec-17 |
30-Jun-18 |
30-Jun-19 |
29-Jun-20 |
29-Jun-21 |
30-Jun-22 |
30-Jun-23 |
29-Jun-24 |
29-Jun-25 |
30-Jun-26 |
Equity Terminal value |
|
Net working capital |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
Tangible fixed assets |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
Operating capital to finance |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
Free cash flow to equity (incl. USO) |
|
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
Excess cash |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
Financial fixed assets |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
Provisions |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
Loans to credit institutions |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
Net financial assets and liabilities |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
Equity |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investor capital injections (-)/dividends (+) |
|
-2 339 |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
Equity IRR |
[…] % |
|
Cost of Equity |
[…] % |
4.1.4.
The capital injections from Denmark and Sweden into PostNord AB do not involve State aid
4.2.
Denmark’s comments on the opening decision
4.3.
Sweden’s comments on the opening decision
4.4.
Comments from Denmark and Sweden on third parties comments
4.4.1.
The three capital injections constitute three separate measures and not one single measure
4.4.2.
The three capital injections were not granted on the date of the October Agreement
4.4.3.
The DCF calculations for PostNord Group capital injection into Post Danmark are sound
|
Capital Asset Pricing Model |
[…] % |
|
Risk premium – Size |
[…] % |
|
Risk premium – digitalisation |
[…] % |
|
Cost of equity |
[…] % |
|
Cost of debt |
[…] % |
|
|
|
|
Equity ratio |
[…] % |
|
Debt ratio |
[…] % |
|
WACC |
[…] % |
|
Note: Tax rate 22 % |
|
5.
ASSESSMENT
5.1.
Qualification of the capital injections as one measure or three separate measures
5.1.1.
Different investors
5.1.2.
Different beneficiaries
5.1.3.
Different purpose
5.1.4.
Requirement to have implementing measures
5.1.5.
Response to the third parties arguments
5.1.6.
Conclusion
5.2.
Date of granting of the capital injections
5.2.1.
Date of granting of the Group capital injection
5.2.1.1.
Assessment
5.2.2.
Date of granting of the Danish capital injection
5.2.3.
Date of granting of the Swedish capital injection
5.3.
Existence of aid
5.3.1.
Capital injection from PostNord Group into Post Danmark
5.3.1.1.
Economic activity and notion of undertaking
5.3.1.2.
Imputability and State resources
5.3.1.3.
Selectivity
5.3.1.4.
Advantage
5.3.1.5.
Distortion of competition and effect on trade
5.3.1.6.
Conclusion
5.3.2.
Capital injection from Denmark into PostNord AB
5.3.2.1.
Economic activity and notion of undertaking
5.3.2.2.
Imputability and State resources
5.3.2.3.
Selectivity
5.3.2.4.
Advantage
Scenario A: Enterprise value with State injections – WACC = Lower WACC (before PostNord AB’s downgrading)
|
Year |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
2026 |
Terminal Value |
Total |
WACC |
Terminal growth rate |
|
NPV |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] % |
[…] % |
|
Time factor |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
||
|
Discount factor |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
||
|
Free Cash Flow |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
Scenario B: Enterprise value without State injections – WACC = Higher WACC
|
Year |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
2026 |
Terminal Value |
Total |
WACC |
Terminal growth rate |
|
NPV |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] % |
[…] % |
|
Time factor |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
||
|
Discount factor |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
||
|
Free Cash Flow |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
Enterprise value with capital injections (Scenario A) |
(A) |
[…] |
|
Enterprise value without capital injections (Scenario B) |
(B) |
[…] |
|
Enterprise value increase due to capital injections |
(C)=(A)-(B) |
1 096 |
|
Capital injections from Denmark and Sweden |
(D) |
667 |
Scenario A: Enterprise value with State injections – WACC = Lower WACC (before PostNord AB’s downgrading)
|
Year |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
2026 |
Terminal Value |
Total |
WACC |
Terminal growth rate |
|
NPV |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] % |
[…] % |
|
Time factor |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
||
|
Discount factor |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
||
|
Free Cash Flow |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
Scenario B: Enterprise value without State injections – WACC = Higher WACC (after PostNord AB’s downgrading) only in 2018-2026 & Lower WACC in perpetuity
|
Year |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
2026 |
Terminal Value |
Total |
WACC |
Terminal growth rate |
|
NPV |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] % until 2026 & […] % from 2026 onwards |
[…] % |
|
Time factor |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
||
|
Discount factor |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
||
|
Free Cash Flow |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
[…] |
|
Enterprise value with capital injections (Scenario A) |
(A) |
[…] |
|
Enterprise value without capital injections (Scenario B) |
(B) |
[…] |
|
Enterprise value increase due to capital injections |
(C)=(A)-(B) |
62 |
|
Capital injections from Denmark and Sweden |
(D) |
667 |